Bicycle Therapeutics Plc (BCYC)
4.34
-0.03
(-0.69%)
USD |
NASDAQ |
Aug 24, 16:00
4.42
+0.08
(+1.84%)
After-Hours: 20:00
Bicycle Therapeutics Gross Profit Margin (Quarterly) : -69.64% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -69.64% |
| March 31, 2026 | -27.28% |
| December 31, 2025 | 97.21% |
| September 30, 2025 | 85.04% |
| June 30, 2025 | 41.92% |
| March 31, 2025 | 83.62% |
| December 31, 2024 | 54.05% |
| September 30, 2024 | 18.84% |
| June 30, 2024 | 82.48% |
| March 31, 2024 | 91.51% |
| December 31, 2023 | 68.97% |
| September 30, 2023 | 68.42% |
| June 30, 2023 | 85.57% |
| March 31, 2023 | 68.20% |
| December 31, 2022 | 56.48% |
| September 30, 2022 | 0.00% |
| June 30, 2022 | 0.00% |
| March 31, 2022 | 0.00% |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Autolus Therapeutics Plc | 55.20% |
| Akari Therapeutics Plc | -- |
| Biodexa Pharmaceuticals Plc | -- |
| DBV Technologies SA | -- |
| Cellectis SA | 15.62% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -32.07% |
| Return on Assets | -26.59% |
| Return on Invested Capital | -31.40% |
| Profit Margin (Quarterly) | -8.00K% |
| Operating Margin (Quarterly) | -9.71K% |
| Return on Net Operating Assets | -1.10K% |